{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038033","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.375899+00:00","generated_at":"2026-06-12T09:11:17.230875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023","bullets":["Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).","Cash and equivalents $116.9M at June 30, 2023, funding operations into first half of 2025.","MM-120 Phase 2b for GAD enrollment target lowered to 180 patients; topline results expected Q4 2023.","MM-120 Phase 2a for ADHD over 80% enrolled; topline readout expected Q4 2023 / Q1 2024.","Exclusive license agreement with Catalent for Zydis ODT formulation of MM-120 for pivotal trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038033","json":"https://secwatch.observer/filing/0000950170-23-038033.json","markdown":"https://secwatch.observer/filing/0000950170-23-038033.md","text":"https://secwatch.observer/filing/0000950170-23-038033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/0000950170-23-038033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/mnmd-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:11:17.230875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efdbf0db1af1d8e3ed16be3ee3b020ded4319cb0","claim":"Definium Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release (the \"Press Release:) announcing its financial results for its fiscal quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/0000950170-23-038033-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}